S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:AQST

Aquestive Therapeutics (AQST) Stock Price, News & Analysis

$2.57
-0.06 (-2.28%)
(As of 02/23/2024 ET)
Today's Range
$2.57
$2.77
50-Day Range
$1.87
$2.79
52-Week Range
$0.72
$2.95
Volume
4.58 million shs
Average Volume
905,120 shs
Market Capitalization
$171.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Aquestive Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
133.5% Upside
$6.00 Price Target
Short Interest
Healthy
2.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Aquestive Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.07) to ($0.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.12 out of 5 stars

Medical Sector

581st out of 939 stocks

Pharmaceutical Preparations Industry

272nd out of 439 stocks


AQST stock logo

About Aquestive Therapeutics Stock (NASDAQ:AQST)

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

AQST Stock Price History

AQST Stock News Headlines

Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Aquestive Therapeutics Inc (AQST)
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Best Momentum Stocks to Buy for November 28th
See More Headlines
Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2023
Today
2/23/2024
Next Earnings (Confirmed)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AQST
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+118.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-54,410,000.00
Pretax Margin
-24.90%

Debt

Sales & Book Value

Annual Sales
$47.68 million
Book Value
($2.19) per share

Miscellaneous

Free Float
61,165,000
Market Cap
$183.62 million
Optionable
Optionable
Beta
2.78
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Daniel Barber (Age 48)
    CEO, President & Director
    Comp: $925.35k
  • Mr. Alexander Mark Schobel (Age 65)
    Chief Innovation & Technology Officer
    Comp: $672.69k
  • Ms. Lori J. Braender BSBA (Age 68)
    Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
    Comp: $678.76k
  • Mr. A. Ernest Toth Jr. (Age 65)
    Chief Financial Officer
    Comp: $679.9k
  • Ms. Cassie Jung (Age 45)
    Senior Vice President of Operations
  • Mr. Peter E. Boyd (Age 58)
    Senior Vice President of IT, HR & Communications
  • Mr. Kenneth W. Marshall (Age 65)
    Chief Commercial Officer
  • Dr. Gary H. Slatko M.D. (Age 67)
    MBA, Chief Medical Officer
  • Dr. Stephen Wargacki (Age 46)
    Senior VP of Research & Development
  • Dr. Carl N. Kraus M.D. (Age 54)
    Chief Medical Officer














AQST Stock Analysis - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings
or view top-rated stocks.

What is Aquestive Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 12 month price objectives for Aquestive Therapeutics' stock. Their AQST share price targets range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 133.5% from the stock's current price.
View analysts price targets for AQST
or view top-rated stocks among Wall Street analysts.

How have AQST shares performed in 2024?

Aquestive Therapeutics' stock was trading at $2.02 on January 1st, 2024. Since then, AQST stock has increased by 27.2% and is now trading at $2.57.
View the best growth stocks for 2024 here
.

Are investors shorting Aquestive Therapeutics?

Aquestive Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 1,740,000 shares, a drop of 8.4% from the January 15th total of 1,900,000 shares. Based on an average trading volume of 599,800 shares, the days-to-cover ratio is presently 2.9 days.
View Aquestive Therapeutics' Short Interest
.

When is Aquestive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our AQST earnings forecast
.

How can I listen to Aquestive Therapeutics' earnings call?

Aquestive Therapeutics will be holding an earnings conference call on Wednesday, March 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.02. The firm had revenue of $10.68 million for the quarter, compared to the consensus estimate of $9.93 million. During the same period in the previous year, the firm posted ($0.38) EPS.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (5.88%), Vanguard Group Inc. (2.83%), Essex Investment Management Co. LLC (1.27%), Vahanian & Associates Financial Planning Inc. (0.89%), Legato Capital Management LLC (0.51%) and Bridgeway Capital Management LLC (0.29%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd.
View institutional ownership trends
.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AQST) was last updated on 2/23/2024 by MarketBeat.com Staff